Search
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54071] It is the first and only therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081] … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigational[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. … Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam].
Axicabtagene ciloleucel
go.drugbank.com/drugs/DB13915ApprovedInvestigational[A216163] Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. … [L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]
Iobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigational[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … cytarabine consolidation, followed by a maintenance monotherapy resulted in a 22% reduction in the risk of death.
Synonyms: N-(5-(1,1-Dimethylethyl)isoxazol-3-yl)-N'-(4-(7-(2-(morpholin-4-yl)ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)ureaOxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalWhile agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular … Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by
Rutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalIt has been used therapeutically to decrease capillary fragility.
Synonyms: 3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-oneMixtures: Rose Hips 500plus Nu Life, Nutriforte Non-Acidic Vitamin C 1000 mg with BioflavonoidsButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines [A177754] thus it is not indicated for such condition.
Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acid